单磷酸阿糖腺苷治疗手足口病的临床分析  

Clinical Analysis of Vidarabine Monophosphate for the Treatment of Hand-Foot-Mouth Disease(HFMD)

作　　者：张劲松[1] 罗如平[1] 

机构地区：[1]湖南省儿童医院,湖南长沙410007

出　　处：《临床医学工程》2015年第1期41-42,共2页Clinical Medicine & Engineering

摘　　要：目的探讨单磷酸阿糖腺苷治疗手足口病的临床效果。方法选取我院近年来收治的80例手足口病患儿随机分为观察组与对照组各40例,分别给予单磷酸阿糖腺苷及利巴韦林治疗,对两组患儿的临床治疗效果、治疗后临床症状及体征变化时间进行观察,比较两组患儿治疗期间不良反应发生情况。结果观察组及对照组治疗总有效率分别为92.5%、70.0%,差异有统计学意义(P<0.05);观察组临床症状及体征有效控制时间明显短于对照组(P<0.05);观察组不良反应发生率与对照组比较无统计学差异(P>0.05)。结论单磷酸阿糖腺苷治疗手足口病能够快速改善临床症状,效果确切,安全性高,可在临床推广使用。Objective To explore the clinical effect of vidarabine monophosphate for the treatment of hand-foot-mouth disease（HFMD）. Methods Eighty cases of HFMD admitted to our hospital were selected and randomly divided into two groups, with 40 cases in each group. The observation group was treated with vidarabine monophosphate, while the control group was treated with ribavirin. The clinical effect and adverse reactions were observed and compared between two groups. Results The total effective rate of observation group was 92.5%, significantly higher than 70.0% of control group（P〈0.05）. The times of effective control of clinical symptoms and signs of observation group were significantly shorter than those of control group（P〈0.05）. There was no statistical difference between two groups in the incidence of adverse reactions（P〉0.05）. Conclusions Vidarabine monophosphate has significant effect for the treatment of HFMD. It can effectively improve the clinical symptoms, with exact effect and high safety, which is worthy of clinical promotion.

关 键 词：单磷酸阿糖腺苷 手足口病 疗效 

分 类 号：R512.5[医药卫生—内科学]